Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
As CEO, my guiding principle in this crisis is simple: You cannot manage a balance sheet if you destroy your soul, and you cannot protect shareholders by killing patients. Delaying disclosure of a fatal side effect to protect a stock price is not only a profound ethical failure; it is corporate suicide.Read the full answer
48-Hour Action Plan: Patient Safety First, Managed Transparency Second Core Decision (Stated Up Front) We report to regulators immediately—voluntarily—and we disclose on the earnings call. The math is brutal and clear: ~500 patients could develop liver failure over 5 years at current prescribing rates (4M ÷ 8,000).Read the full answer